Investor Relations

A leadership story in the field of advanced cell therapy

Day High:
Day Low:
Copyright West LLC. Minimum 15 minutes delayed.

Investor Relations

Press Releases

October 14, 2020

Vericel Announces Preliminary Third Quarter 2020 Total Net Revenues of $32 Million

October 9, 2020

Vericel To Host Virtual Analyst and Investor Day on October 16, 2020

September 16, 2020

Vericel Announces FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns

Events and Presentations



More information is coming soon.

Stock Quote & Analyst Coverage

Stock Quote ()

Today's Open
Previous Close
Today's High
Today's Low
52 Week High
52 Week Low
Vericel Corporation is covered by the following analysts.
Ryan Zimmerman
Swayampakula Ramakanth
H.C. Wainwright & Co.
Jeff Cohen
Ladenburg Thalmann
Danielle Antalffy
Chad Messer
Kevin DeGeeter
Kaila Krum

Vericel Corporation is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Vericel Corporation's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Vericel Corporation or its management. Vericel Corporation does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.